Inmune Bio, Inc. 10-K — AI Bull & Bear Analysis

The 10-K reveals a company at a critical crossroads, shifting from a diversified clinical-stage biotech to a focused, single-asset play. The successful data from the CORDStrom trial provides a legitimate path to revenue, but the financial reality is stark: the company is burning cash rapidly and is explicitly warned about its ability to continue as a going concern. The strategic write-down of the Alzheimer's asset reflects a necessary admission of failure in that program, but it also removes a secondary pillar of value. Ultimately, the investment thesis hinges on whether the 2026 regulatory window opens fast enough to provide a valuation uplift that allows the company to raise capital without destroying shareholder value. The asymmetry is high; success in the RDEB market would be transformative, but the lack of a diversified pipeline and the looming liquidity crisis create a high probability of significant further dilution or operational failure if regulatory delays occur.